Chase Pharmaceuticals Corp
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2016 | $12 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Aug 2015 | $4 M | No. 3 | $2 to $10 million | equity, options | SEC | |
| May 2014 | $6 M | No. 2 | $2 to $10 million | equity, options | SEC | |
| Nov 2010 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Chase Pharmaceuticals Corp chose not to state its revenue in its newest notice of a funding round (Mar 2016).
SEC Form D · Mar 2016
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2016
That is all the official record says: Chase Pharmaceuticals Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Chase Pharmaceuticals Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 14 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Kathleen N. Clarence-Smith | Executive officer | Mar 2016 |
| Thomas N. Chase | Executive officer | Mar 2016 |
| John M. Reher | Executive officer | Feb 2016 |
| John M. Siebert | Executive officer | Aug 2015 |
| Kathleen P. Clarence-Smith | Executive officer | Jan 2011 |
| Richard P. Dulik | Executive officer | Jan 2011 |
| John M. Reher | Director | Mar 2016 |
| Karoly N. Nikolich | Director | Mar 2016 |
| Nayan Greg Parekh | Director | Mar 2016 |
| Raphael M. Wisniewski | Director | Mar 2016 |
| Stephen N. Cunningham | Director | Mar 2016 |
| Thomas N. Chase | Director | Mar 2016 |
| Vikram M. Sudarsan | Director | Mar 2016 |
| Douglas Ingram | Director | Feb 2016 |
| N. Greg Parekh | Director | Aug 2015 |
| Greg N. Parekh | Director | May 2014 |
| John M. Siebert | Director | May 2014 |
| Raphael N. Wisniewski | Director | May 2014 |
| Vikram N. Sudarsan | Director | May 2014 |
| John M Reher | Director | Jan 2011 |
| Karoly M Nikolich | Director | Jan 2011 |
| Kathleen P. Clarence-Smith | Director | Jan 2011 |